Pakistan calls for polio vaccination in high-security districts
This article was originally published in Scrip
Executive Summary
The Pakistan Secretary of Health has named delivering polio vaccines to children a "top priority", as areas affected by security in the North-West Frontier Province (NWFP) and Federal Administered Tribal Areas (FATA) of the country become inaccessible to vaccination teams. The Health Secretary, Khushnood Akhtar Lashari, urged officials from the Provincial Health Department of NWFP to include polio eradication as part of negotiations with local militants, during an emergency meeting between the federal ministry of health for NWFP and FATA. Additional Secretary for Health, Imtiaz Inayat Elahi, also called for the implementation of polio teams within restricted areas, as well as special vaccination points at entrances to districts where access is limited. Special arrangements were made to focus a current polio campaign in high-risk areas, launched on July 28th, and Mr Lashari said the Prime Minister was also being requested to launch a national polio campaign in August.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).